X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

PhRMA urges USTR to protect American innovators abroad

By Mark Grayson  |    February 10, 2017
Yesterday, PhRMA submitted comments for the 2017 Special 301 Report the Office of the U.S. Trade Representative (USTR) will publish in April. The comments highlight serious intellectual property...   Read More

New report provides recommendations for securing and protecting IP

By Mark Grayson  |    December 13, 2016
This week, the White House Office of the U.S. Intellectual Property Enforcement Coordinator (IPEC) issued a Joint Strategic Plan outlining actions government, industry, educational institutions...   Read More

New report highlights need to speed patent examination

By Mark Grayson  |    November 2, 2016
The Center for the Protection of Intellectual Property released a new report, “The Long Wait for Innovation: The Global Patent Pendency Problem,” documenting the growing global challenge of patent...   Read More

Study highlights negative impact of Canada's promise doctrine on R and D investment

By Mark Grayson  |    October 21, 2016
A newly published study from Charles River Associates (CRA) has found that Canada’s approach to intellectual property (IP), innovation and patient care is being jeopardized because of its adoption...   Read More

New report highlights impact of intellectual property on U.S. economy

By Mark Grayson  |    October 13, 2016
In late September, the U.S. Department of Commerce released a comprehensive report that found intellectual property (IP) intensive industries contribute more than $6 trillion (38.2 percent) to...   Read More

Fact Check Friday: The truth about biopharmaceutical patents

By Mark Grayson  |    August 26, 2016
MYTH: Biopharmaceutical companies use government-protected monopolies to raise costs on medicines. FACT: Patent-protected medicines routinely face competition from other brand name medicines,...   Read More

Guest Post: New threats could fundamentally alter innovation in drug manufacturing

By Guest Contributor  |    August 2, 2016
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

The importance of the Bayh-Dole Act

By Setareh Samii  |    July 12, 2016
Over 35 years ago, leaders in Washington D.C. united in what would today be a strikingly bipartisan manner to pass the University and Small Business Patent Procedures Act of 1980 – better known as...   Read More

The next step towards Colombia’s future

By Mark Grayson  |    July 6, 2016
Just a few weeks ago in Havana, Colombia’s President Juan Manuel Santos and Commander of the Revolutionary Armed Forces of Colombia or FARC, Timoleon Jimenez, made history when they signed a peace...   Read More

Forced pharmaceutical localization fails to deliver

By Guest Contributor  |    June 15, 2016
  Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates